Abstracts tagged "Renal disease"

Abstract Number: 181 • 2019 ACR/ARP Annual Meeting
Prevalence of Renal Impairment in a US Rheumatoid Arthritis Population
Jon Giles¹, Lee Simon ², Janet Pope ³, Jim Paik ⁴, Michael Grabner ⁵, Amanda Quebe ⁶, Carol Gaich ⁶, Claudia Salinas ⁶ and Jeffrey Curtis ⁷, ¹Division of Rheumatology, Columbia University, New York, NY, ²SDG LLC, Cambridge, ³Western University, London, ON, Canada, ⁴Eli Lilly & Company, Indianapolis, IN, ⁵HealthCore, Inc., Wilmington, DE, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Clinical management of rheumatoid arthritis (RA) must consider patient renal function, particularly for medications that rely on renal clearance and require dose adjustment or…
Abstract Number: 335 • 2019 ACR/ARP Annual Meeting
Renal Transplant Complications in Patients with and Without Gout
Megan Francis-Sedlak¹, Brian LaMoreaux ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Graft-related complications are among the most serious issues solid-organ transplant recipients and their healthcare teams face post-operatively. Gout is a known frequent co-morbidity in…
Abstract Number: 337 • 2019 ACR/ARP Annual Meeting
Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study
Alka Mithal ¹, Maanek Sehgal ² and Gurkirpal Singh¹, ¹ICORE, Woodside, ²UCLA, Los Angeles
Background/Purpose: Gout is a disorder of uric acid metabolism and often presents as acute severe joint pain. Previous work from our group suggests that all-cause…
Abstract Number: 638 • 2019 ACR/ARP Annual Meeting
Longitudinal Trends for Estimated Glomerular Filtration Rate and Predictors of Change in Patients with Systemic Lupus Erythematosus
Terry Cheuk Fung Yip ¹, Michelle Petri ² and Laurence Magder³, ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: To characterize the longitudinal trajectory of estimated glomerular filtration rate (eGFR) in patients with systemic lupus erythematosus (SLE) and identify predictors of change in…
Abstract Number: 1102 • 2019 ACR/ARP Annual Meeting
Estimate of Prevalence of Secondary Distal Renal Tubular Acidosis Among Patients with Sjogren’s Syndrome and Systemic Lupus Erythematosus in a US Population with Employer-Sponsored Health Insurance
Gary Bryant¹, Linda Law ² and Josephine Li-McLeod ³, ¹University of Minnesota Medical School, Minneapolis, MN, ²Advicenne, Cincinnati, OH, ³Stratevi, Boston, MA
Background/Purpose: Distal renal tubular acidosis (dRTA) involves impairment in the distal tubule, leading to insufficient renal acid secretion, which can result in metabolic acidosis, hypokalemia,…
Abstract Number: 2730 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease
Paul Miller¹, Arkadi Chines ², Ben-Hur Albergaria ³, Evelien Gielen ⁴, Bente Langdahl ⁵, Akimitsu Miyauchi ⁶, Mark Vanderkelen ⁷, Cassandra Milmont ², Judy Maddox ² and Jonathan Adachi ⁸, ¹Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, CO, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of Espirito Santo, Vitória, Brazil, ⁴Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Aging, KU Leuven & Center for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷UCB Pharma, Brussels, Belgium, ⁸McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Osteoporosis and renal insufficiency are coexisting disease states in a substantial proportion of postmenopausal women. Since bisphosphonates are generally contraindicated in patients with estimated…
Abstract Number: 2733 • 2018 ACR/ARHP Annual Meeting
From a Myth to a Menace: Increased Disease Severity and Poor Outcomes in an Urban Cohort of African-American Patients with ANCA-Associated Vasculitis
Kathleen Maksimowicz-McKinnon¹, Philip McCarthy², Sandeep Soman³ and John McKinnon³, ¹Rheumatology, Henry Ford Hospital, Detroit, MI, ²Michigan State University College of Osteopathic Medicine, East Lansing, MI, ³Henry Ford Hospital, Detroit, MI
Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic inflammatory disorder frequently associated with significant disability and morbidity, which may lead to end-stage renal disease…
Abstract Number: 139 • 2017 ACR/ARHP Annual Meeting
No Effect of Tumor Necrosis Factor-a Inhibitors on Renal Function in Patients with Rheumatoid Arthritis from Kobio Registry from 2012 to 2016
Seong-Kyu Kim¹, Jung-Yoon Choe², Sung-Hoon Park³ and Hwajeong Lee², ¹Rheumatology, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ²Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ³Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South)
Background/Purpose: Renal disease is prevalent in patients with rheumatoid arthritis (RA), although the precise prevalence of RA has not been determined. Increased mortality in patients…
Abstract Number: 895 • 2017 ACR/ARHP Annual Meeting
Temporal Trends in Incidence and Outcomes of End-Stage Renal Disease Due to Granulomatosis with Polyangiitis in the US from 1995-2014
Zachary S. Wallace¹, Yuqing Zhang², Leo Lu³, John H. Stone⁴ and Hyon K. Choi⁵, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Temporal Trends in Incidence and Outcomes of End-Stage Renal Disease due to Granulomatosis with Polyangiitis in the US from 1995-2014 Background/Purpose: Granulomatosis with polyangiitis (GPA)…
Abstract Number: 1679 • 2017 ACR/ARHP Annual Meeting
Different Cut-Offs for Renal Resistive Index Reflect Renal and Other Organ Involvement and Predict Worsening in SSc Patients
Cosimo Bruni¹, Vanessa Maestripieri², Giulia Tesei³, Marco Chiostri⁴, Serena Guiducci³, Silvia Bellando-Randone¹, Maria Boddi⁴ and Marco Matucci-Cerinic³, ¹Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ²Department of Internal Medicine, Division of Medicine for Care Complexity III, University of Florence, Florence, Italy, ³Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁴Department of Heart and Vessels, Division of Cardiology I, University of Florence, Florence, Italy
Background/Purpose: Renal Resistive Index (RRI), measured by Doppler ultrasound, reflects changes in both renal vascular and tubular-interstitial compartments and systemic vascular compliance related to age…
Abstract Number: 1713 • 2017 ACR/ARHP Annual Meeting
Defining Genetic Risk for Scleroderma Renal Crisis in RNA-Polymerase III Antibody Positive Patients
Edward Stern¹, Sandra Guerra¹, Harry Chinque¹, David Gonzalez Serna², Markella Ponticos¹, Javier Martin², Maureen D. Mayes³, Shervin Assassi⁴, Carmen Fonseca¹ and Christopher Denton⁵, ¹UCL Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ²Instituto de Parasitología y Biomedicina López-Neyra, Granada, Spain, ³Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴University of Texas McGovern Medical School, Houston, TX, ⁵Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC), characterised by accelerated hypertension and acute kidney injury, is a life-threatening complication of systemic sclerosis (SSc). Most SSc cases have…
Abstract Number: 1789 • 2017 ACR/ARHP Annual Meeting
Improved Survival with Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System
Zachary S. Wallace¹, Rachel Wallwork², Leo Lu³, John H. Stone⁴, Yuqing Zhang⁵ and Hyon K. Choi⁶, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Improved Survival with Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data SystemBackground/Purpose: Granulomatosis with polyangiitis (GPA) is a…
Abstract Number: 2671 • 2017 ACR/ARHP Annual Meeting
Bosentan in Scleroderma Renal Crisis: A National Open Label Prospective Study
Alice Bérezné^1,2, Hendy ABDOUL³, Alexandre Karras⁴, Isabelle Marie⁵, Antoine Huart⁶, Maxence Ficheux⁷, Viviane Queyrel⁸, Bernard Imbert⁹, Xavier Puéchal¹, Arnaud Hot¹⁰, Boris Bienvenu¹¹, Elisabeth Diot¹², Bruno Moulin¹³, Thomas Quémeneur¹⁴, Jean-Emmanuel Kahn¹⁵, Luc Mouthon¹ and Loïc Guillevin for the French Vasculitis Study Group¹, ¹Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ²Centre de Compétence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Centre de Compétence Eosinophiles CEREO, Hôpital Annecy Genevois, Anency, France, ³Centre d'investigation Clinique Paris Descartes, Necker–Cochin, Paris, Unité de Recherche Clinique, paris, France, ⁴Nephrology, HEGP, Paris, France, ⁵Internal medicine, Hôpital Bois Guillaume, ROUEN, France, ⁶Nephrology, Hôpital Rangueil, Toulouse, France, ⁷Nephrologie, Hôpital Clémenceau, CAEN, France, ⁸Internal medicine, Hôpital de l'Archet, NICE, France, ⁹Grenoble, Grenoble, France, ¹⁰Department of Internal Medicine, Edouard Herriot University Hospital, Hospices Civils de Lyon, Lyon cedex 03, France, ¹¹Internal Medicine, Hôpital de la côte de Nacre, Caen, France, ¹²Pôle médecine interne et gériatrique, pneumologie, Hôpital Bretonneau, Tours, France, ¹³Nephrology, Hôpital Civil, STRASBOURG, France, ¹⁴Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ¹⁵foch hospital, foch, France
Background/Purpose: Scleroderma renal crisis (SRC), a life-threatening complication of systemic sclerosis (SSc), arises despite therapy combining an angiotensin-converting–enzyme inhibitor (AECI) and/or dialysis. Endothelin-1 (ET-1), a…
Abstract Number: 2813 • 2016 ACR/ARHP Annual Meeting
Risk of Renal Failure within 10 or 20 Years of SLE Diagnosis, By Patient Characteristics
Laurence S Magder¹, Erik Barr² and Michelle Petri³, ¹Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ²Epidemiology, University of Maryland, Baltimore, MD, ³Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at elevated risk for lupus nephritis and ultimately renal failure. While some risk factors for renal…
Abstract Number: 1911 • 2015 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma
Edward Stern^1,2, Cassandra Hong², Voon H. Ong², Aine Burns¹, Robert Unwin³ and Christopher P. Denton⁴, ¹Nephrology, Royal Free Hospital, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Nephrology, UCL Division of Medicine, London, United Kingdom, ⁴Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Renal disease in scleroderma (SSc), including scleroderma renal crisis (SRC), remains a major clinical challenge. Previous studies showed up to 50% of SSc patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].